Decheng Capital »

Lyell Immunopharma shares owned by Decheng Capital

Quarter-by-quarter ownership of Lyell Immunopharma shares owned by Decheng Capital from 13F filings

Historical chart of Decheng Capital investment in Lyell Immunopharma

Tip: Access up to 7 years of quarterly data

All positions including Lyell Immunopharma held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lyell Immunopharma by Decheng Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $9.7M 596k 16.24
2025-06-30 $5.3M 596k 8.84
2025-03-31 $6.4M 12M 0.54
2024-12-31 $7.6M 12M 0.64

More positions owned by Decheng Capital

Cg Oncology (CGON)
Nuvation Bio (NUVB)
Upstream Bio (UPB)
Aardvark Therapeutics (AARD)
Newamsterdam Pharma Co Nv (NAMS)
Merus N V (MRUS)
Revolution Medicines (RVMD)
Lyell Immunopharma
BeyondSpring SHS (BYSI)
Aclaris Therapeutics (ACRS)
Arcus Biosciences Incorporated (RCUS)
Equillium (EQ)
Crinetics Pharmaceuticals In (CRNX)
Krystal Biotech (KRYS)
Aura Biosciences (AURA)

View all positions for Decheng Capital

Top funds holding Lyell Immunopharma

Decheng Capital
Takeda Pharmaceutical

View all funds holding Lyell Immunopharma